A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).

Lori J GoldsteinMauro MansuttiChristelle LevyJenny C ChangStephanie HenryIsaura Fernandez-PerezJana PrausovàElzbieta StaroslawskaGiuseppe VialeBeth ButlerSusan McCannaPier Adelchi RuffiniMax S WichaAnne F Schottnull null

Published in: Breast cancer research and treatment (2021)

NCT01861054/February 24, 2015.

Keyphrases

placebo controlled
double blind
small cell lung cancer
squamous cell carcinoma
open label
phase iii
phase ii
study protocol
phase ii study
clinical trial
chemotherapy induced
randomized controlled trial